Funded Biotechnology Startups in South San Francisco
South San Francisco's biotech corridor accounts for 50 tracked funding events in this dataset, spanning October 2020 through November 2025.
South San Francisco's biotech corridor accounts for 50 tracked funding events in this dataset, spanning October 2020 through November 2025. The two largest rounds are Cytokinetics at $550M and Structure Therapeutics at $547M, both closed in Q2 2024, followed by Insitro's $400M Series C in March 2021 and ArsenalBio's $325M Series C in September 2024. The most recent entries are The EVERY Company's $55M Series D in November 2025 and Kardigan's $254M Series B in October 2025.
Round types skew heavily toward undisclosed stages; among labeled rounds, Series A is the most common, with recipients including Centivax, Shinobi Therapeutics, and NGM Biopharmaceuticals. Therapeutics companies dominate, but the dataset also includes diagnostic platforms (Freenome, InterVenn, Earli), longevity research (NewLimit), microbiome engineering (Novome Biotechnologies, Federation Bio), and computational drug discovery (Insitro, Deep Origin). Twelve rounds closed in 2025 through November, ranging from $1M to $254M.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest rounds in this dataset?
The two largest rounds are Cytokinetics at $550M and Structure Therapeutics at $547M, both closed in Q2 2024. Behind them sit Insitro's $400M Series C (March 2021), ArsenalBio's $325M Series C (September 2024), IDEAYA Biosciences at $263M (July 2024), and Kardigan's $254M Series B (October 2025).
How much funding activity has occurred in 2025 among these companies?
Twelve rounds closed in South San Francisco biotech between January and November 2025 within these 50 rows. Kardigan's $254M Series B and Surrozen's $175M are the largest, followed by NewLimit's $130M Series B, Vera Therapeutics at $75M, Freenome at $50M, and Centivax's $45M Series A. The range runs down to $1M for Titan Pharmaceuticals and Senti Biosciences.
Which round stage appears most often among these 50 entries?
Series Unknown — rounds where the stage was not publicly disclosed — is by far the most common classification. Among labeled stages, Series A is the most frequent, with recipients including Centivax, Trace Neuroscience, Shinobi Therapeutics, NGM Biopharmaceuticals, GenEdit, Epic-Bio, TRex Bio, Ambys Medicines, and Earli, spread across 2021 through 2025.
Are there diagnostic or non-therapeutic companies in these rows?
Yes. Diagnostic and detection platforms include Freenome ($50M, August 2025), Earli ($40M Series A, January 2021), MiNDERA Corporation (two separate rounds in 2022 and 2024), and InterVenn ($201M Series C, August 2021). Non-therapeutic entries also span longevity research (NewLimit, $130M Series B), microbiome engineering (Novome Biotechnologies, Federation Bio), cell therapy manufacturing (Cellares), and food biotechnology (The EVERY Company, $55M Series D).
Do any companies appear more than once in these 50 rows?
Two companies appear twice: MiNDERA Corporation raised a $14M round in July 2024 and a $2M debt financing in June 2022; InterVenn closed a $201M Series C in August 2021 following a $34M round in November 2020.
What post-IPO activity is represented in this dataset?
Three entries are classified as Post-IPO Equity: Annexon Biosciences ($130M, July 2022), Day One Biopharmaceuticals ($173M, June 2022), and Fluidigm ($250M, January 2022). All three closings fell within a seven-month window in 2022; no post-IPO rounds appear in the 2023–2025 portion of the dataset.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.